Other Species / Isoforms
  ARPP-19 (human)      LTP 

LTP (Low Throughput Papers) : The number of records in which this modification site was determined using methods other than discovery mass spectrometry.

 HTP 

HTP (High Throughput Papers): The number of records in which this modification site was assigned using ONLY proteomic discovery mass spectrometry.

 
S2-p
______MsAEVPEAA
0 7
ARPP-19 (human) ______MsAEVPEAA S2-p
ARPP-19 iso2 (human) gap -
ARPP-19 (mouse) ______MsAEVPEAA S2-p
ARPP-19 (rat) ______MsAEVPEAA S2-p
ARPP-19 (frog) _MSGENQETKAQEES E7
S10-p
AEVPEAAsAEEQKEM
0 5
ARPP-19 (human) AEVPEAAsAEEQKEM S10-p
ARPP-19 iso2 (human) gap -
ARPP-19 (mouse) AEVPEAAsAEEQKEM S10-p
ARPP-19 (rat) AEVPEAASAEEQKEM S10
ARPP-19 (frog) TKAQEESSALEQKEI S15
K20
EQKEMEDKVtsPEkA
0 1
ARPP-19 (human) EQKEMEDKVtsPEkA K20
ARPP-19 iso2 (human) ____MEDKVTSPEKA K4
ARPP-19 (mouse) EQKEMEDKVtsPEKA K20
ARPP-19 (rat) EQKEMEDkVTSPEKA K20-ac
ARPP-19 (frog) EQKEIDDKVVSPEKS K25
T22-p
KEMEDKVtsPEkAEE
0 2
ARPP-19 (human) KEMEDKVtsPEkAEE T22-p
ARPP-19 iso2 (human) __MEDKVTSPEKAEE T6
ARPP-19 (mouse) KEMEDKVtsPEKAEE T22-p
ARPP-19 (rat) KEMEDkVTSPEKAEE T22
ARPP-19 (frog) KEIDDKVVSPEKSEE V27
S23-p
EMEDKVtsPEkAEEA
0 19
ARPP-19 (human) EMEDKVtsPEkAEEA S23-p
ARPP-19 iso2 (human) _MEDKVTSPEKAEEA S7
ARPP-19 (mouse) EMEDKVtsPEKAEEA S23-p
ARPP-19 (rat) EMEDkVTSPEKAEEA S23
ARPP-19 (frog) EIDDKVVSPEKSEEI S28
K26-ac
DKVtsPEkAEEAkLk
0 4
ARPP-19 (human) DKVtsPEkAEEAkLk K26-ac
ARPP-19 iso2 (human) DKVTSPEKAEEAKLK K10
ARPP-19 (mouse) DKVtsPEKAEEAKLK K26
ARPP-19 (rat) DkVTSPEKAEEAkLK K26
ARPP-19 (frog) DKVVSPEKSEEIKLK K31
K31-ac
PEkAEEAkLkAryPH
0 4
ARPP-19 (human) PEkAEEAkLkAryPH K31-ac
ARPP-19 iso2 (human) PEKAEEAKLKARYPH K15
ARPP-19 (mouse) PEKAEEAKLKARyPH K31
ARPP-19 (rat) PEKAEEAkLKARYPH K31-ac
ARPP-19 (frog) PEKSEEIKLKARYPN K36
K33-ac
kAEEAkLkAryPHLG
0 1
ARPP-19 (human) kAEEAkLkAryPHLG K33-ac
ARPP-19 iso2 (human) KAEEAKLKARYPHLG K17
ARPP-19 (mouse) KAEEAKLKARyPHLG K33
ARPP-19 (rat) KAEEAkLKARYPHLG K33
ARPP-19 (frog) KSEEIKLKARYPNLG K38
R35-m1
EEAkLkAryPHLGQk
0 1
ARPP-19 (human) EEAkLkAryPHLGQk R35-m1
ARPP-19 iso2 (human) EEAKLKARYPHLGQK R19
ARPP-19 (mouse) EEAKLKARyPHLGQK R35
ARPP-19 (rat) EEAkLKARYPHLGQk R35
ARPP-19 (frog) EEIKLKARYPNLGPK R40
Y36-p
EAkLkAryPHLGQkP
0 25
ARPP-19 (human) EAkLkAryPHLGQkP Y36-p
ARPP-19 iso2 (human) EAKLKARYPHLGQKP Y20
ARPP-19 (mouse) EAKLKARyPHLGQKP Y36-p
ARPP-19 (rat) EAkLKARYPHLGQkP Y36
ARPP-19 (frog) EIKLKARYPNLGPKP Y41
K42-ac
ryPHLGQkPGGsDFL
0 4
ARPP-19 (human) ryPHLGQkPGGsDFL K42-ac
ARPP-19 iso2 (human) RYPHLGQKPGGSDFL K26
ARPP-19 (mouse) RyPHLGQKPGGSDFL K42
ARPP-19 (rat) RYPHLGQkPGGSDFL K42-ac
ARPP-19 (frog) RYPNLGPKPGGSDFL K47
K42-ub
ryPHLGQkPGGsDFL
0 2
ARPP-19 (human) ryPHLGQkPGGsDFL K42-ub
ARPP-19 iso2 (human) RYPHLGQKPGGSDFL K26
ARPP-19 (mouse) RyPHLGQKPGGSDFL K42
ARPP-19 (rat) RYPHLGQKPGGSDFL K42
ARPP-19 (frog) RYPNLGPKPGGSDFL K47
S46-p
LGQkPGGsDFLRKRL
0 2
ARPP-19 (human) LGQkPGGsDFLRKRL S46-p
ARPP-19 iso2 (human) LGQKPGGSDFLRKRL S30
ARPP-19 (mouse) LGQKPGGSDFLRKRL S46
ARPP-19 (rat) LGQkPGGSDFLRKRL S46
ARPP-19 (frog) LGPKPGGSDFLRKRL S51
K58-ac
KRLQKGQkyFDsGDy
0 20
ARPP-19 (human) KRLQKGQkyFDsGDy K58-ac
ARPP-19 iso2 (human) KRLQKGQKYFDsGDY K42
ARPP-19 (mouse) KRLQKGQkyFDsGDy K58-ac
ARPP-19 (rat) KRLQKGQkyFDsGDy K58-ac
ARPP-19 (frog) KRLQKGQKYFDSGDY K63
K58-ub
KRLQKGQkyFDsGDy
0 6
ARPP-19 (human) KRLQKGQkyFDsGDy K58-ub
ARPP-19 iso2 (human) KRLQKGQKYFDsGDY K42
ARPP-19 (mouse) KRLQKGQkyFDsGDy K58-ub
ARPP-19 (rat) KRLQKGQKyFDsGDy K58
ARPP-19 (frog) KRLQKGQKYFDSGDY K63
Y59-p
RLQKGQkyFDsGDyN
Upstream
0 344
Treatment
  • erlotinib
ARPP-19 (human) RLQKGQkyFDsGDyN Y59-p
ARPP-19 iso2 (human) RLQKGQKYFDsGDYN Y43
ARPP-19 (mouse) RLQKGQkyFDsGDyN Y59-p
ARPP-19 (rat) RLQKGQkyFDsGDyN Y59-p
ARPP-19 (frog) RLQKGQKYFDSGDYN Y64
S62-p
KGQkyFDsGDyNMAk
Upstream
Downstream
4 115
ARPP-19 (human)
S62-p
ARPP-19 (mouse)
S62-p
ARPP-19 (rat)
S62-p
Effects on Modified Protein
  • enzymatic activity, inhibited
  • molecular association, regulation
Effects on Biological Processes:
  • cell cycle regulation
Kinase, in vitro:
  • MASTL (human)
  • PKACA (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • angiotensin-(1-7)
  • antibody
  • metastatic potential
  • nocodazole
  • okadaic_acid
ARPP-19 (human) KGQkyFDsGDyNMAk S62-p
ARPP-19 iso2 (human) KGQKYFDsGDYNMAK S46-p
ARPP-19 (mouse) KGQkyFDsGDyNMAK S62-p
ARPP-19 (rat) KGQkyFDsGDyNMAK S62-p
ARPP-19 (frog) KGQKYFDSGDYNMAK S67
Y65-p
kyFDsGDyNMAkAkM
Upstream
1 553
Treatment
  • ephrin_B1
  • ephrin_B2
  • erlotinib
  • FGF2
  • gefitinib
  • Su11274
  • U0126
ARPP-19 (human) kyFDsGDyNMAkAkM Y65-p
ARPP-19 iso2 (human) KYFDsGDYNMAKAKM Y49
ARPP-19 (mouse) kyFDsGDyNMAKAKM Y65-p
ARPP-19 (rat) kyFDsGDyNMAKAKM Y65-p
ARPP-19 (frog) KYFDSGDYNMAKAKM Y70
K69-ub
sGDyNMAkAkMKNKQ
0 6
ARPP-19 (human) sGDyNMAkAkMKNKQ K69-ub
ARPP-19 iso2 (human) sGDYNMAKAKMKNKQ K53
ARPP-19 (mouse) sGDyNMAKAKMKNKQ K69
ARPP-19 (rat) sGDyNMAKAKMKNKQ K69
ARPP-19 (frog) SGDYNMAKAKMKNKQ K74
K71-ub
DyNMAkAkMKNKQLP
0 1
ARPP-19 (human) DyNMAkAkMKNKQLP K71-ub
ARPP-19 iso2 (human) DYNMAKAKMKNKQLP K55
ARPP-19 (mouse) DyNMAKAKMKNKQLP K71
ARPP-19 (rat) DyNMAKAKMKNKQLP K71
ARPP-19 (frog) DYNMAKAKMKNKQLP K76
T79-p
MKNKQLPtAAPDkTE
0 1
ARPP-19 (human) MKNKQLPtAAPDkTE T79-p
ARPP-19 iso2 (human) MKNKQLPTAAPDKTE T63
ARPP-19 (mouse) MKNKQLPAAAPDKTE A79
ARPP-19 (rat) MKNKQLPAAAPDkTE A79
ARPP-19 (frog) MKNKQLPTAASDKTE T84
K84-ac
LPtAAPDkTEVTGDH
0 2
ARPP-19 (human) LPtAAPDkTEVTGDH K84-ac
ARPP-19 iso2 (human) LPTAAPDKTEVTGDH K68
ARPP-19 (mouse) LPAAAPDKTEVTGDH K84
ARPP-19 (rat) LPAAAPDkTEVTGDH K84-ac
ARPP-19 (frog) LPTAASDKTEVTGDH K89
T94-p
VTGDHIPtPQDLPQR
0 5
ARPP-19 (human) VTGDHIPtPQDLPQR T94-p
ARPP-19 iso2 (human) VTGDHIPTPQDLPQR T78
ARPP-19 (mouse) VTGDHIPTPQDLPQR T94
ARPP-19 (rat) VTGDHIPTPQDLPQR T94
ARPP-19 (frog) VTGDHIPTPQDLPQR T99
K102-ub
PQDLPQRkPsLVAsk
0 1
ARPP-19 (human) PQDLPQRkPsLVAsk K102-ub
ARPP-19 iso2 (human) PQDLPQRKPSLVASK K86
ARPP-19 (mouse) PQDLPQRKPsLVAsK K102
ARPP-19 (rat) PQDLPQRKPsLVASk K102
ARPP-19 (frog) PQDLPQRKPSLVAsK K107
S104-p
DLPQRkPsLVAskLA
Upstream
2 118
Kinase, in vitro:
  • PKACA (human)
  • PKG1 (human)
Putative upstream phosphatases:
  • PPP2CA (human)
Treatment
  • CysNO
  • DEA-NONOate
  • iloprost
  • ischemia
  • okadaic_acid
  • SNP
ARPP-19 (human) DLPQRkPsLVAskLA S104-p
ARPP-19 iso2 (human) DLPQRKPSLVASKLA S88
ARPP-19 (mouse) DLPQRKPsLVAsKLA S104-p
ARPP-19 (rat) DLPQRKPsLVASkLA S104-p
ARPP-19 (frog) DLPQRKPSLVAsKLA S109
S108-p
RkPsLVAskLAG___
1 7
ARPP-19 (human) RkPsLVAskLAG___ S108-p
ARPP-19 iso2 (human) RKPSLVASKLAG___ S92
ARPP-19 (mouse) RKPsLVAsKLAG___ S108-p
ARPP-19 (rat) RKPsLVASkLAG___ S108
ARPP-19 (frog) RKPSLVAsKLAG___ S113-p
K109-ac
kPsLVAskLAG____
0 9
ARPP-19 (human) kPsLVAskLAG____ K109-ac
ARPP-19 iso2 (human) KPSLVASKLAG____ K93
ARPP-19 (mouse) KPsLVAsKLAG____ K109
ARPP-19 (rat) KPsLVASkLAG____ K109-ac
ARPP-19 (frog) KPSLVAsKLAG____ K114